Multiple Myeloma Clinical Trial

Non-invasive MRD Assessment in Multiple Myeloma

Summary

The purpose of this study is to investigate the sensitivity and accuracy of non-invasive MRD assessment using liquid biopsy (blood draw) and functional imaging (whole body MRI) in participants with new diagnosed and previously treated multiple myeloma. The long-term goal of this study is to investigate whether non-invasive methods for MRD assessment can replace bone marrow aspiration and biopsy in a substantial percentage of participants with multiple myeloma.

View Full Description

Full Description

There is an unmet clinical need for an easier, non-invasive, and reliable method to perform MRD assessments that can be used in clinical trials and routine practice. The two non-invasive modalities that are most promising for MRD assessment are liquid biopsy to detect circulating tumor cells (CTCs) and functional imaging to detect focal myeloma lesions. However, there are no prospective data on the sensitivity and specificity of non-invasive MRD assessment with respect to the gold standard of bone marrow sampling.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Adults age ≥18 years
Patients with newly diagnosed multiple myeloma
Patients with previously treated multiple myeloma with a maximum of two prior lines of therapy
Expected life expectancy of greater than one year and intention to start a new line of treatment

Exclusion Criteria:

Patients without cognitive capacity to give informed consent for participation
Patients with contraindications to MRI, which include the following:
Claustrophobia, which, at investigator's discretion, would prohibit patient from undergoing whole body diffusion-weighted magnetic resonance imaging (WB-DWI)
Pacemaker
Metallic implants, which would prohibit patient from undergoing MRI All subjects will be screened for any contraindication to MRI as per their guidelines at the time of patient enrollment.
Patients must not receive granulocyte colony stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF) injection within 1 week prior to WB-DWI.
Patients must not have been initiated on treatment prior to baseline disease assessment by bone marrow aspiration/biopsy and/or WB-DWI Up to 160 mg of dexamethasone (or equivalent) and/or 1 dose of bortezomib (+/- Cyclophosphamide-Dexamethasone) is allowed prior to disease assessment by bone marrow aspiration and WB-DWI.

Study is for people with:

Multiple Myeloma

Estimated Enrollment:

88

Study ID:

NCT05625971

Recruitment Status:

Recruiting

Sponsor:

Rajshekhar Chakraborty, MD

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

New York Presbyterian Hospital/Columbia University Irving Medical Center
New York New York, 10032, United States More Info
Research Nurse Navigator
Contact
212-342-5162
[email protected]
Rajshekhar Chakraborty, MD
Principal Investigator

How clear is this clinincal trial information?

Study is for people with:

Multiple Myeloma

Estimated Enrollment:

88

Study ID:

NCT05625971

Recruitment Status:

Recruiting

Sponsor:


Rajshekhar Chakraborty, MD

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.